PDCD1 and neoplasm: The most prevalent tumor types in the cohort of 79 patients included lung cancer (23, 29.1%), esophageal carcinoma (19, 24.1%), and gastric cancer (15, 19.0%), with the majority of patients receiving anti-PD-1 therapy (71, 89.9%).